Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 10/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.33 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22198967 | 0.83 | GRIA1 (0.37) | IDH1KDM4EGRIA1CACNG8GRIN2D | |
| SCHEMBL22185229 | 0.83 | IDH1 (0.57) | IDH1KDM4E | |
| SCHEMBL22184888 | 0.80 | IDH1 (0.36) | IDH1KDM4EGRIA1CACNG8 | |
| SCHEMBL22185228 | 0.77 | HRH4 (0.43) | IDH1KDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL17603389 | 0.72 | IDH1 (0.55) | IDH1KDM4E | |
| SCHEMBL17603543 | 0.72 | IDH1 (0.55) | IDH1KDM4E | |
| SCHEMBL22185380 | 0.70 | GRIN2D (0.46) | IDH1KDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL13104127 | 0.68 | HTR2A (0.42) | PGK1DDR1 | |
| SCHEMBL22185211 | 0.67 | TNF (0.41) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL22185381 | 0.67 | KDM4E (0.53) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | IDH1 1/4885PGK1 918/4885KDM4E 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.